Lyra Therapeutics (LYRA) Net Margin (2021 - 2025)
Historic Net Margin for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 23936.0%.
- Lyra Therapeutics' Net Margin fell 178472800.0% to 23936.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 3527.52%, marking a year-over-year increase of 101632700.0%. This contributed to the annual value of 4023.11% for FY2023, which is 325100.0% up from last year.
- Lyra Therapeutics' Net Margin amounted to 23936.0% in Q3 2025, which was down 178472800.0% from 4063.93% recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Net Margin registered a high of 828.6% during Q4 2024, and its lowest value of 129290.91% during Q4 2022.
- Moreover, its 5-year median value for Net Margin was 4220.3% (2024), whereas its average is 17265.09%.
- In the last 5 years, Lyra Therapeutics' Net Margin plummeted by -1242661900bps in 2022 and then soared by 1189100900bps in 2023.
- Quarter analysis of 5 years shows Lyra Therapeutics' Net Margin stood at 5024.72% in 2021, then crashed by -2473bps to 129290.91% in 2022, then skyrocketed by 92bps to 10380.82% in 2023, then surged by 108bps to 828.6% in 2024, then crashed by -2989bps to 23936.0% in 2025.
- Its last three reported values are 23936.0% in Q3 2025, 4063.93% for Q2 2025, and 4670.49% during Q1 2025.